Merck KGaA is a healthcare/pharma company that I have been covering and investing in for about 2 years at this point. Q2 2024 ...

MilliporeSigma continued its march of manufacturing investments this year, revealing plans to pump $76 million into expanding ...

Merck KGaA, Darmstadt, Germany, a leading science and technology company, and Intel Corporation, one of the world’s largest semiconductor designers and manufacturers, have begun the implementation of ...

Founded on the principles of innovation and patient need, Theriva™ Biologics is a diversified clinical-stage company focused on developing groundbreaking therapeutics to combat cancer and related ...

Theriva Biologics (TOVX) announced selection as one of five finalists for Merck KGaA’s EMEA Advance Biotech Grant. Finalists for the ...

Merck's consistent dividend payments over 34 years, healthy balance sheet, and attractive valuation highlight its investment ...

Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced ...

Its top-selling treatment, Keytruda, will lose patent protection in a few years. Then Merck will face biosimilar competition ...

While Merck's oncology powerhouse Keytruda delivered another multibillion-dollar sales haul in the third quarter, regional ...

The company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its animal health ...

Theriva Biologics (TOVX) announced selection as one of five finalists for Merck KGaA’s EMEA Advance Biotech Grant. Finalists for the grant will present to a six-judge panel from Merck’s ...

Merck KGaA’s EMEA Advance Biotech Grant Program celebrates standout emerging biotech companies, and winners receive financial support and guidance on navigating their path to commercialization ...